Brown Advisory Inc. decreased its position in shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 5.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,014,842 shares of the company's stock after selling 368,357 shares during the period. Brown Advisory Inc. owned approximately 1.57% of LifeStance Health Group worth $44,329,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Jennison Associates LLC increased its holdings in shares of LifeStance Health Group by 278.4% in the fourth quarter. Jennison Associates LLC now owns 8,086,380 shares of the company's stock worth $59,597,000 after buying an additional 5,949,438 shares during the period. Dimensional Fund Advisors LP increased its stake in LifeStance Health Group by 87.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,524,529 shares of the company's stock worth $25,977,000 after purchasing an additional 1,643,390 shares during the period. Vanguard Group Inc. lifted its position in LifeStance Health Group by 7.9% in the fourth quarter. Vanguard Group Inc. now owns 10,689,396 shares of the company's stock valued at $78,781,000 after purchasing an additional 784,818 shares during the last quarter. First Trust Advisors LP purchased a new stake in shares of LifeStance Health Group during the fourth quarter valued at approximately $4,535,000. Finally, First Eagle Investment Management LLC grew its holdings in shares of LifeStance Health Group by 182.8% in the fourth quarter. First Eagle Investment Management LLC now owns 785,666 shares of the company's stock worth $5,790,000 after purchasing an additional 507,826 shares during the last quarter. Institutional investors own 85.50% of the company's stock.
Insider Buying and Selling
In other LifeStance Health Group news, insider Lisa K. Miller sold 18,845 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.90, for a total transaction of $130,030.50. Following the completion of the transaction, the insider now owns 339,810 shares of the company's stock, valued at approximately $2,344,689. This trade represents a 5.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 6.60% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the stock. KeyCorp initiated coverage on shares of LifeStance Health Group in a report on Tuesday, April 8th. They issued an "overweight" rating and a $9.00 price target on the stock. William Blair reissued an "outperform" rating on shares of LifeStance Health Group in a research note on Friday, February 28th. Finally, Canaccord Genuity Group started coverage on LifeStance Health Group in a report on Thursday, April 3rd. They issued a "buy" rating and a $8.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $8.30.
Get Our Latest Research Report on LFST
LifeStance Health Group Stock Down 1.4 %
Shares of LFST stock traded down $0.08 during midday trading on Friday, reaching $5.73. 2,860,646 shares of the stock were exchanged, compared to its average volume of 1,643,470. LifeStance Health Group, Inc. has a 1 year low of $4.64 and a 1 year high of $8.61. The firm has a market cap of $2.23 billion, a PE ratio of -22.04 and a beta of 1.30. The company's 50 day moving average is $6.70 and its two-hundred day moving average is $7.25. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.19.
LifeStance Health Group Company Profile
(
Free Report)
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
Further Reading

Before you consider LifeStance Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeStance Health Group wasn't on the list.
While LifeStance Health Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.